Detection of hepatic metastasis: Manganese- and ferucarbotran-enhanced MR imaging

European Journal of Radiology

Volumn 60, Issue 1, 2006, Pages 84-90

  Choi, Jin Young ^a   Kim, Myeong Jin ^b   Kim, Joo Hee ^b   Kim, Seung Hyoung ^b   Ko, Heung Kyu ^b   Lim, Joon Seok ^b   Oh, Young Taik ^b   Chung, Jae Joon ^b   Yoo, Hyung Sik ^b   Lee, Jong Tae ^b   Kim, Ki Whang ^b  

^a Seoul National University Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Contrast agent; Liver; Metastasis; MRI

Indexed keywords

CONTRAST AGENT; CONTRAST-TO-NOISE RATIOS (CNR); HEPATIC METASTASIS; METASTASIS;

BIOLOGICAL ORGANS; DIAGNOSIS; DISEASES; MANGANESE; MEDICAL IMAGING; RADIOLOGY;

MAGNETIC RESONANCE IMAGING;

FERUCARBOTRAN; MANGAFODIPIR; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FERUCARBOTRAN NUCLEAR MAGNETIC RESONANCE IMAGING; HISTOLOGY; HUMAN; LIVER METASTASIS; MALE; MANGAFODIPIR TRISODIUM NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGIST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; STUDENT T TEST;

ADULT; AGED; CONTRAST MEDIA; DEXTRANS; EDETIC ACID; FEMALE; FERROSOFERRIC OXIDE; HUMANS; IMAGE ENHANCEMENT; IRON; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; OXIDES; PYRIDOXAL PHOSPHATE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33748693499     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2006.06.016     Document Type: Article

References (25)

1. Hagspiel K.D., Neidl K.F., Eichenberger A.C., Weder W., and Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 196 (1995) 471-478
2. Ros P.R., Freeny P.C., Harms S.E., et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196 (1995) 481-488
3. Seneterre E., Taourel P., Bouvier Y., et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 200 (1996) 785-792
4. Bluemke D.A., Paulson E.K., Choti M.A., DeSena S., and Clavien P.A. Detection of hepatic lesions in candidates for surgery: comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT. AJR Am J Roentgenol 175 (2000) 1653-1658
5. Ward J., Naik K.S., Guthrie J.A., Wilson D., and Robinson P.J. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210 (1999) 459-466
6. Reimer P., Muller M., Marx C., et al. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration-preliminary clinical experience with dynamic T1-weighted MR imaging. Radiology 209 (1998) 831-836
7. Oudkerk M., Torres C.G., Song B., et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 223 (2002) 517-524
8. Bartolozzi C., Donati F., Cioni D., et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 14 (2004) 14-20
9. Kim K.W., Kim A.Y., Kim T.K., et al. Small (< or =2 cm) hepatic lesions in colorectal cancer patients: detection and characterization on mangafodipir trisodium-enhanced MRI. AJR Am J Roentgenol 182 (2004) 1233-1240
10. Kim S.K., Kim S.H., Lee W.J., et al. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. AJR Am J Roentgenol 179 (2002) 741-750
11. Kim M.J., Kim J.H., Lim J.S., et al. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 20 (2004) 612-621
12. Hamm B., Vogl T.J., Branding G., et al. Focal liver lesions: MR imaging with Mn-DPDP-initial clinical results in 40 patients. Radiology 182 (1992) 167-174
13. Sahani D.V., O'Malley M.E., Bhat S., Hahn P.F., and Saini S. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results. J Comput Assist Tomogr 26 (2002) 216-222
14. Kim Y.K., Lee J.M., Kim C.S., Chung G.H., Kim C.Y., and Kim I.H. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 15 (2005) 220-228
15. Imam K., and Bluemke D.A. MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 8 (2000) 741-756
16. Reimer P., Schneider G., and Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14 (2004) 559-578
17. Huppertz A., Balzer T., Blakeborough A., et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230 (2004) 266-275
18. Hussain S.M., De Becker J., Hop W.C., Dwarkasing S., and Wielopolski P.A. Can a single-shot black-blood T2-weighted spin-echo echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spin-echo sequence for the liver? An optimization and feasibility study. J Magn Reson Imaging 21 (2005) 219-229
19. Naganawa S., Sato C., Nakamura T., et al. Diffusion-weighted images of the liver: comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide. J Magn Reson Imaging 21 (2005) 836-840
20. Del Frate C., Bazzocchi M., Mortele K.J., et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 225 (2002) 766-772
21. Weinmann H.J., Ebert W., Misselwitz B., and Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 46 (2003) 33-44
22. Schneider G., Maas R., Schultze Kool L., et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38 (2003) 85-94
23. Wang C., Gordon P.B., Hustvedt S.O., et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 38 (1997) 665-676
24. Wang C., Johansson L., Western A., Fagertun H., and Ahlstrom H. Sequence optimization in mangafodipir trisodium-enhanced liver and pancreas MRI. J Magn Reson Imaging 9 (1999) 280-284
25. Nelson R.C., Chezmar J.L., Newberry L.B., Malko J.A., Gedgaudas-McClees R.K., and Bernardino M.E. Manganese dipyridoxyl diphosphate. Effect of dose, time, and pulse sequence on hepatic enhancement in rats. Invest Radiol 26 (1991) 569-573